TIL Therapy: Understanding Tumor-Infiltrating Lymphocyte Treatment

What Is TIL Therapy? (And How It Differs from CAR-T)

Tumor-Infiltrating Lymphocyte (TIL) therapy is an advanced form of adoptive cell transfer. Unlike CAR-T, which extracts T-cells from the blood and genetically engineers them, TIL therapy extracts immune cells directly from the patient's own tumor, multiplies them by the billions in a laboratory, and reinfuses them to attack the cancer.

Regulatory Status: Approved vs. Investigational

The Surgical Requirement: Why Tumor Resection Is Mandatory

A critical distinction of TIL therapy is that it cannot begin without a viable tumor sample. Patients must undergo a surgical resection (removal) of a tumor lesion to harvest the lymphocytes.

The Treatment Journey: What to Expect

1. Tumor Resection: Surgical removal of a tumor lesion.
2. Manufacturing (3–5 weeks): The tissue is sent to a specialized lab where TILs are isolated and expanded to billions of cells.
3. Lymphodepletion: A short course of chemotherapy to make space in the immune system for the new cells.
4. TIL Infusion: The expanded cells are infused back into the patient (similar to a blood transfusion).
5. High-Dose IL-2 Administration: This is a critical phase. Patients receive multiple doses of Interleukin-2 (IL-2) to help the TIL cells survive and multiply in the body. This phase often requires intensive monitoring, as high-dose IL-2 can cause significant side effects like capillary leak syndrome, low blood pressure, and fluid retention — frequently necessitating ICU-level care.

Eligibility: The Strict Gatekeepers

Access to approved TIL therapy is highly restricted. Treating centers will rigorously evaluate:

• Prior Treatment Failure: Documented progression after standard immunotherapies (e.g., pembrolizumab, nivolumab) and targeted therapies (if BRAF-mutated).
• Surgical Candidacy: Ability to safely undergo tumor resection.
• Organ Function: Adequate heart, lung, liver, and kidney function to withstand lymphodepletion and high-dose IL-2.
• Performance Status: Patients must be relatively active (e.g., ECOG 0–1) to tolerate the intensive recovery period.

Unspoken Questions: Addressing Your Concerns

"Will this treatment work for me?"

TIL therapy is not a guaranteed cure. In the pivotal C-144-01 clinical trial for advanced melanoma, the overall response rate was approximately 30–40%, with a subset of patients achieving durable, long-term remission. However, individual responses vary widely based on tumor biology and immune health. Any source promising a guaranteed outcome is not being transparent.

"Is traveling to another country for this worth the risk?"

This is a deeply personal decision with significant trade-offs. Consider: Can your body tolerate long-haul travel with active cancer? Can you afford to stay near the treatment center for 6–8 weeks for surgical recovery and IL-2 monitoring? Will your home-country oncologist accept your records and manage long-term follow-up? There is no universal "right" answer — only what is safest and most feasible for your specific situation.

"What happens if the treatment doesn't work?"

It is vital to have a "Plan B" discussion with your oncologist before starting. If TIL therapy does not achieve the desired response, options may include enrollment in other clinical trials, alternative systemic therapies (if not yet exhausted), or a shift to palliative care focused on maximizing quality of life and symptom management.

Global Access Landscape: A Data-Driven Overview

CancerCareE does not recommend specific hospitals or countries. However, understanding the global landscape can help you and your oncologist identify viable pathways:

• Commercial Access: As of mid-2026, FDA-approved Amtagvi is commercially accessible in the United States and, following Health Canada's August 2025 approval, in Canada. Iovance withdrew its EU marketing authorization application in July 2025 after EMA raised concerns about efficacy and safety data; the product does not currently hold EMA approval. It does not yet hold NMPA (China) approval for commercial use.
• Clinical Trial Volume: Based on publicly available data from ClinicalTrials.gov, the United States hosts the highest number of active TIL clinical trials, followed by China, with select early-phase trials occurring in Germany, Japan, and other regions.
• Published Research: Peer-reviewed literature on TIL outcomes is predominantly led by major academic cancer centers in the US, China, and parts of Europe.

Explore TIL by Cancer Type

TIL therapy is approved or being investigated for specific cancer types. Select your diagnosis to learn more.

Product Intelligence

Approved and investigational TIL products. Select a product for detailed information.

Decision Tools & Resources

Comprehensive guides to help you understand TIL therapy requirements and make informed decisions.

What Records May a TIL Center Request?

To evaluate your candidacy, a specialized center will typically require:

• Pathology & Biomarkers: Recent biopsy reports confirming diagnosis and mutation status (e.g., BRAF V600).
• Imaging: Recent PET/CT or MRI scans to assess tumor burden and, crucially, resectability (whether a tumor can be safely removed).
• Treatment History: Detailed records of all prior systemic therapies, dates, and documented responses or progression.
• Clinical Status: Recent blood work, cardiac evaluation (e.g., echocardiogram), and pulmonary function tests to ensure fitness for surgery and IL-2.

Questions to Ask Your Treating Oncologist

1. Based on my specific tumor location and health, am I a realistic candidate for the required tumor resection surgery?
2. Given my prior treatments, what is my realistic probability of response to TIL therapy based on current clinical data?
3. What is this specific center's experience with TIL therapy, and how do they manage high-dose IL-2 toxicity?
4. What is the expected total duration of stay near the hospital, including surgical recovery and IL-2 monitoring?
5. If TIL therapy is not successful, what is our predefined "Plan B"?

How CancerCareE Works

CancerCareE is strictly an independent patient information and introduction platform. We are not a medical tourism agency, a healthcare provider, or a clinical facilitator. We do not review, store, or handle patient medical records.

1. Explore & Learn: Use our independent guides to understand TIL therapy requirements and global access pathways.
2. Request an Introduction: Fill out a simple contact form with your name and phone number. (No medical records are required or accepted at this stage).
3. Partner Connection: We securely share your contact details with a vetted partner hospital or a specialized medical facilitation agency in your region of interest.
4. Direct Consultation: The partner institution will contact you directly. They will request your medical records, assess clinical eligibility, discuss costs, and manage logistical arrangements.
5. Our Role Ends Here: CancerCareE does not participate in clinical evaluations, treatment decisions, patient dispatch, or post-introduction logistics. All responsibilities lie solely with the treating institution or facilitation agency.

Frequently Asked Questions

What is the main difference between TIL and CAR-T?

TIL therapy extracts naturally occurring immune cells directly from a patient's tumor via surgery and multiplies them. CAR-T extracts T-cells from the blood and genetically engineers them to target a specific protein. They are distinct therapies with different approval statuses, procedures, and side effect profiles.

Is TIL therapy approved for cancers other than melanoma?

As of mid-2026, FDA approval for TIL therapy (Amtagvi) is specific to advanced, previously treated melanoma. Its use in cervical cancer, lung cancer, and other solid tumors is currently limited to registered clinical trials and is not an approved standard of care.

Why is surgery required for TIL therapy?

TIL therapy relies on extracting lymphocytes that have already infiltrated the patient's tumor. Therefore, a surgical resection of a tumor lesion is mandatory to obtain the necessary tissue for laboratory expansion. Patients who are not surgical candidates are generally not eligible for TIL therapy.

Who makes the final decision about TIL eligibility?

Eligibility is determined exclusively by the licensed multidisciplinary clinical team (including surgical and medical oncologists) at the certified treating institution, based on your specific pathology, imaging, prior treatments, and overall fitness for the procedure.